Mineralys Therapeutics Investor Presentation — March 2024

Document content

1 Mineralys Therapeutics, Inc. ©2023. All Rights Reserved.

Targeting Aldosterone in the

Treatment of Cardiorenal

Mar ch 20242 Mineralys Therapeutics, Inc. ©2023. All Rights Reserved.

We caution you that this presentation contains forward -looking statements. All statements other than statements of historical fa cts contained in this presentation, including

statements regarding our future results of operations and financial position, business strategy, research and development pla ns, the anticipated timing, costs, design, and

conduct of our ongoing and planned preclinical studies and planned clinical trials for lorundrostat and any future product ca ndidates, the timing and likelihood of regulatory

filings and approvals for lorundrostat and any future product candidates, our ability to commercialize our product candidates , if approved, the potential to develop future

product candidates, the potential benefits of strategic collaborations and our intent to enter into any strategic arrangement s, the timing and likelihood of success, and plans

and objectives of management for future operations and future results of anticipated product development efforts, are forward -looking statements. In some cases, you can

identify forward -looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,”

“estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The inclusion of forward -looking statements should not be

regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties

inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorun drostat; potential delays in the commencement,

enrollment, and completion of clinical trials and nonclinical studies; our dependence on third parties in connection with man ufacturing, research and clinical and nonclinical

testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory ap proval, and/or commercialization; unfavorable

results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not ne cessarily predictive of future results; our reliance on our

exclusive license with Mitsubishi Tanabe to provide us with intellectual property rights to develop and commercialize lorundr ostat; our ability to obtain and maintain

intellectual property protection for lorundrostat; we may use our capital resources sooner than we expect; our ability to mai ntain undisrupted business operations due to the